Colorectal cancer (CRC) is associated with lifestyle factors that affect insulin/IGF signaling, of which the insulin receptor substrate 1 (IRS1) is a key transducer. We investigated expression, localization and pathologic correlations of IRS1 in cancer-uninvolved colonic epithelium, primary CRCs with paired liver metastases and in vitro polarizing Caco2 and HT29 cells. IRS1 mRNA and protein resulted higher, relative to paired mucosa, in adenomas of familial adenomatous polyposis patients and in CRCs that overexpressed c-MYC, ？-catenin, InsR？, and IGF1R. Analysis of IRS1 immunostaining in 24 cases of primary CRC with paired colonic epithelium and hepatic metastasis showed that staining intensity was significantly higher in metastases relative to both primary CRC (P<0.01) and colonic epithelium (P<0.01). Primary and metastatic CRCs, compared to colonic epithelium, contained significantly higher numbers of IRS1-positive cells (P = 0.013 and P = 0.014, respectively). Pathologic correlations in 163 primary CRCs revealed that diffuse IRS1 staining was associated with tumors combining differentiated phenotype and aggressive markers (high Ki67, p53, and ？-catenin). In Caco 2 IRS1 and InsR were maximally expressed after polarization, while IGF1R was highest in pre-polarized cells. No nuclear IRS1 was detected, while, with polarization, phosphorylated IRS1 (pIRS1) shifted from the lateral to the apical plasma membrane and was expressed in surface cells only. In HT29, that carry mutations constitutively activating survival signaling, IRS1 and IGF1R decreased with polarization, while pIRS1 localized in nuclear spots throughout the course. Overall, these data provide evidence that IRS1 is modulated according to CRC differentiation, and support a role of IRS1 in CRC progression and liver metastatization.
References
[1]
Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366–78.
[2]
Johnson IT, Lund EK (2007) Review article: nutrition, obesity and colorectal cancer. Aliment Pharmacol Ther 26: 161–81.
[3]
World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR press.
[4]
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915–28.
[5]
Haydon AM, Macinnis RJ, English DR, Morris H, Giles GG (2006) Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut 55: 689–94.
[6]
Ngo TH, R. Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ (2002) Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro. Cancer Causes Control 13: 929–935.
[7]
Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC (2005) The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 20: 203–20.
[8]
Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131(11 Suppl): 3109S–20S.
[9]
Sandhu MS, Dunger DB, Giovannucci EL (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94: 972–80.
[10]
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and Cancer: A Consensus Report. CA Cancer J Clin 60: 207–221.
[11]
Guo YS, Narayan S, Yallampalli C, Singh P (1992) Characterization of insulin like growth factor I receptors in human colon cancer. Gastroenterology 102: 1101–8.
[12]
Bach SP, Renehan AG, Potten CS (2000) Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 21: 469–476.
[13]
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469–8.
[14]
Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159–70.
[15]
Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, et al. (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280: 596–9.
[16]
Yang J, Zhang W, Evans PM, Chen X, He X, et al. (2006) Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 281: 17751–7.
[17]
van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241–50.
[18]
White MF (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413–22.
[19]
Bommer GT, Feng Y, Iura A, Giordano TJ, Kuick R, et al. (2010) IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem 285: 1928–38.
[20]
Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV (2007) Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6: 705–13.
[21]
Ramocki NM, Wilkins HR, Magness ST, Simmons JG, Scull BP, et al. (2008) Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9. Endocrinology 149: 261–7.
[22]
Rousset M (1986) The human colon carcinoma cell lines HT-29 and Caco-2: two in vitro models for the study of intestinal differentiation. Biochimie 68: 1035–1040.
[23]
Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953–61.
[24]
Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, et al. (2006) Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Ann Oncol 17: Suppl 7vii91–6.
[25]
Mahdavinia M, Bishehsari F, Verginelli F, Cumashi A, Lattanzio R, et al. (2008) P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol 216: 543–50.
[26]
Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, et al. (2010) A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One 5: e10456.
[27]
Modica S, Morgano A, Salvatore L, Petruzzelli M, Vanier MT, et al. (2009) Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2. Gut 58: 1250–9.
[28]
S？？f AM, Halbleib JM, Chen X, Yuen ST, Leung SY, et al. (2007) Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer. Mol Biol Cell 18: 4245–60.
[29]
Chantret I, Barbat A, Dussaulx E, Brattain MG, Zweibaum A (1988) Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res 48: 1936–42.
[30]
Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF (1997) Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 94: 10330–34.
[31]
Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, et al. (2000) APC mutations in sporadic colorectal tumors: A mutational “hotspot" and interdependence of the “two hits". Proc Natl Acad Sci USA 97: 3352–57.
[32]
Yuan Z, Sotsky Kent T, Weber TK (2003) Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene 22: 6304–10.
[33]
Half E, Bercovich D, Rozen P (2009) Familial adenomatous polyposis. Orphanet J Rare Dis 4: 22.
[34]
Chang Q, Li Y, White MF, Fletcher JA, Xiao S (2002) Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 62: 6035–38.
[35]
Simmons JG, Ling Y, Wilkins H, Fuller CR, D'Ercole AJ, et al. (2007) Cell-specific effects of insulin receptor substrate-1 deficiency on normal and IGF-I-mediated colon growth. Am J Physiol Gastrointest Liver Physiol 293: G995–1003.
[36]
Ewton DZ, Kansra S, Lim S, Friedman E (2002) Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of forkhead1, initially mitogenic, then mediating growth arrest and differentiation. Int J Cancer 98: 665–73.
[37]
Howarth GS (2003) Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J Nutr 133: 2109–12.
[38]
Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, et al. (2002) Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82: 1377–89.
[39]
Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205–11.
[40]
Shaw LM (2001) Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 21: 5082–93.
[41]
Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, et al. (2008) Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci 99: 879–87.
[42]
Shen L, Toyota M, Kondo Y, Lin E, Zhang L, et al. (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104: 18654–59.
[43]
Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561–73.
[44]
Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, et al. (2007) Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther 6: 1143–50.
Yokoyama S, Takifuji K, Hotta T, Matsuda K, Tominaga T, et al. (2010) Moderately differentiated colorectal adenocarcinoma as a lymph node metastatic phenotype: comparison with well differentiated counterparts. BMC Surgery 10: 8.
[47]
Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, et al. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071–74.
[48]
Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, et al. (1999) Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19: 7203–15.
[49]
Sánchez-Aragó M, Chamorro M, Cuezva JM (2010) Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 31: 567–76.
[50]
Chiang JM, Yeh CY, Changchien CR, Chen JS, Tang R, et al. (2010) Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups. Int J Colorectal Dis 25: 941–47.
[51]
Zarrilli R, Pignata S, Romano M, Gravina A, Casola S, et al. (1994) Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of Caco-2 human colon carcinoma cells. Cell Growth Differ 5: 1085–91.
[52]
MacDonald RS, Thornton WH Jr, Bean TL (1993) Insulin and IGF-1 receptors in a human intestinal adenocarcinoma cell line (Caco-2): regulation of Na+ glucose transport across the brush border. J Recept Res 13: 1093–1113.
[53]
Serhan MF, Kreydiyyeh SI (2010) Insulin down-regulates the Na(+)/K(+) ATPase in enterocytes but increases intestinal glucose absorption. Gen Comp Endocrinol 167: 228–33.
[54]
Carraway CA, Carraway KL (2007) Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis. Sci STKE 2007(381): re3.
[55]
Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, et al. (1992) des-(1-3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer 52: 910–17.
[56]
Wu A, Chen J, Baserga R (2008) Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 27: 397–403.
[57]
Drakas R, Tu X, Baserga R (2004) Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 101: 9272–76.
[58]
Wu A, Sciacca L, Baserga R (2003) Nuclear translocation of insulin receptor substrate-1 by the insulin receptor in mouse embryo fibroblasts. J Cell Physiol 195: 453–60.
[59]
Tu X, Wu A, Maiorana A, Baserga R (2003) Subcellular localization of IRS-1 in cell proliferation and differentiation. Horm Metab Res 35: 734–39.
[60]
Prisco M, Santini F, Baffa R, Liu M, Drakas R, et al. (2002) Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor. J Biol Chem 277: 32078–85.
[61]
Chen J, Wu A, Sun H, Drakas R, Garofalo C, et al. (2005) Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin. J Biol Chem 280: 29912–20.
[62]
Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, et al. (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res: 70: 6412–19.
[63]
Sehat B, Tofigh A, Lin Y, Trocmé E, Liljedahl U, et al. (2010) SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 2010 3: ra10.
